114 related articles for article (PubMed ID: 16616058)
1. Preanalytical pitfalls of blood sampling to measure true circulating matrix metalloproteinase 9 and tissue inhibitors of matrix metalloproteinases.
Jung K; Gerlach RF; Tanus-Santos JE
Clin Chim Acta; 2006 Nov; 373(1-2):180-1; author reply 182. PubMed ID: 16616058
[No Abstract] [Full Text] [Related]
2. Preanalytical biases in measurement of matrix metalloproteinases and their tissue inhibitors in peripheral blood.
Jung K
J Rheumatol; 2007 Apr; 34(4):890-2; author reply 892. PubMed ID: 17407248
[No Abstract] [Full Text] [Related]
3. Variations with time of plasma concentrations of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2.
Rossignol P; Jacob MP; Cambillau M; Mouradian D; Plouin PF; Chatellier G
Thromb Res; 2007; 119(2):261-3. PubMed ID: 16530811
[No Abstract] [Full Text] [Related]
4. Serum or plasma: what kind of blood sample should be used to measure circulating matrix metalloproteinases and their inhibitors?
Jung K
J Neuroimmunol; 2005 May; 162(1-2):1-2. PubMed ID: 15833353
[No Abstract] [Full Text] [Related]
5. Increased circulatory MMP-2 and MMP-9 levels and activities in patients with type 1 diabetes mellitus.
Shiau MY; Tsai ST; Tsai KJ; Haung ML; Hsu YT; Chang YH
Mt Sinai J Med; 2006 Nov; 73(7):1024-8. PubMed ID: 17195891
[TBL] [Abstract][Full Text] [Related]
6. Validating sampling methods for measurement of circulating matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1.
Zhang RY; Cui W; Zhao KJ; Tang YQ; Li L
Pancreas; 2010 Aug; 39(6):937; author reply 937-8. PubMed ID: 20664481
[No Abstract] [Full Text] [Related]
7. Prestorage leukoreduction prevents accumulation of matrix metalloproteinase 9 in stored blood.
Frake PC; Smith HE; Chen LF; Biffl WL
Arch Surg; 2006 Apr; 141(4):396-400; discussion 400. PubMed ID: 16618899
[TBL] [Abstract][Full Text] [Related]
8. Heparin affects matrix metalloproteinases and tissue inhibitors of metalloproteinases circulating in peripheral blood.
Mannello F; Jung K; Tonti GA; Canestrari F
Clin Biochem; 2008 Dec; 41(18):1466-73. PubMed ID: 18926810
[TBL] [Abstract][Full Text] [Related]
9. The value of sequential serum measurements of gelatinases and tissue inhibitors during chemotherapy in ovarian cancer.
Rauvala M; Turpeenniemi-Hujanen T; Puistola U
Anticancer Res; 2006; 26(6C):4779-84. PubMed ID: 17214341
[TBL] [Abstract][Full Text] [Related]
10. Measurement of matrix metalloproteinases and their tissue inhibitors in serum produces doubtful results.
Jung K
J Infect Dis; 2008 Dec; 198(11):1722-3; author reply 1723-4. PubMed ID: 19000015
[No Abstract] [Full Text] [Related]
11. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes].
Florys B; Głowińska B; Urban M; Peczyńska J
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):184-9. PubMed ID: 17020653
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinases (MMP): determination of different forms by different techniques may require different preanalytical strategies.
Fainardi E; Castellazzi M; Bellini T; Dallocchio F
Mult Scler; 2007 May; 13(4):561-2. PubMed ID: 17463079
[No Abstract] [Full Text] [Related]
13. Serum or plasma samples? The "Cinderella" role of blood collection procedures: preanalytical methodological issues influence the release and activity of circulating matrix metalloproteinases and their tissue inhibitors, hampering diagnostic trueness and leading to misinterpretation.
Mannello F
Arterioscler Thromb Vasc Biol; 2008 Apr; 28(4):611-4. PubMed ID: 18354094
[No Abstract] [Full Text] [Related]
14. Matrix metalloproteinase and tissue inhibitor expression in atherosclerotic and nonatherosclerotic thoracic aortic aneurysms.
Schmoker JD; McPartland KJ; Fellinger EK; Boyum J; Trombley L; Ittleman FP; Terrien C; Stanley A; Howard A
J Thorac Cardiovasc Surg; 2007 Jan; 133(1):155-61. PubMed ID: 17198804
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy.
Roldán V; Marín F; Gimeno JR; Ruiz-Espejo F; González J; Feliu E; García-Honrubia A; Saura D; de la Morena G; Valdés M; Vicente V
Am Heart J; 2008 Jul; 156(1):85-91. PubMed ID: 18585501
[TBL] [Abstract][Full Text] [Related]
16. Temporal disparity in the induction of matrix metalloproteinases and tissue inhibitors of metalloproteinases after thoracic aortic aneurysm formation.
Barbour JR; Stroud RE; Lowry AS; Clark LL; Leone AM; Jones JA; Spinale FG; Ikonomidis JS
J Thorac Cardiovasc Surg; 2006 Oct; 132(4):788-95. PubMed ID: 17000289
[TBL] [Abstract][Full Text] [Related]
17. Blood sampling as critical preanalytical determinant to use circulating MMP and TIMP as surrogate markers for pathological processes.
Jung K; Meisser A; Bischof P
Int J Cancer; 2005 Oct; 116(6):1000-1; author reply 1002-3. PubMed ID: 15856460
[No Abstract] [Full Text] [Related]
18. MMP and TIMP alterations in asymptomatic and symptomatic severe recurrent carotid artery stenosis.
Sapienza P; Borrelli V; di Marzo L; Cavallaro A
Eur J Vasc Endovasc Surg; 2009 May; 37(5):525-30. PubMed ID: 19297218
[TBL] [Abstract][Full Text] [Related]
19. A differential release of matrix metalloproteinases 9 and 2 during coronary artery bypass grafting and off-pump coronary artery bypass surgery.
Sokal A; Zembala M; Radomski A; Kocher A; Pacholewicz J; Los J; Jedrzejczyk E; Zembala M; Radomski M
J Thorac Cardiovasc Surg; 2009 May; 137(5):1218-24. PubMed ID: 19379995
[TBL] [Abstract][Full Text] [Related]
20. Gelatinase A (MM-2), gelatinase B (MMP-9) and their inhibitors (TIMP 1, TIMP-2) in serum of women with endometriosis: Significant correlation between MMP-2, MMP-9 and their inhibitors without difference in levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in relation to the severity of endometriosis.
Salata IM; Stojanovic N; Cajdler-Łuba A; Lewandowski KC; Lewiński A
Gynecol Endocrinol; 2008 Jun; 24(6):326-30. PubMed ID: 18584412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
